Skip to Main Content

Paper Details

RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome.
Clin Lung Cancer
8
2023
Author NameAffiliation
Edward B GaronDavid Geffen School of Medicine at university of california los angeles
Edward B GaronDavid Geffen School of Medicine at university of california los angeles
  • 1 - 2

Datasets

Release 1.2